# A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

> **NCT05503693** · PHASE1 · COMPLETED · sponsor: **Alebund Pty Ltd** · enrollment: 62 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** AP303 50 μg
- **DRUG:** AP303 150 μg
- **DRUG:** AP303 300 μg
- **DRUG:** AP303 600 μg
- **DRUG:** Placebo 50 μg
- **DRUG:** Placebo 150 μg
- **DRUG:** Placebo 300 μg
- **DRUG:** Placebo 600 μg

## Key facts

- **NCT ID:** NCT05503693
- **Lead sponsor:** Alebund Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-06
- **Primary completion:** 2023-07-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05503693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05503693, "A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05503693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*